Iveric gains as study shows eye disorder drug helps cut potential vision loss

IVERIC bio

01/03/2023 16:47

** Shares of eye disease drugmaker Iveric Bio  ISEE.O  rise 16.4% to $24.19
    ** Co says data from trial of its investigational drug shows up to a 59%
reduction in rate of vision loss compared to sham treatment at 12 months 
    ** Avacincaptad pegol (ACP) is an investigational drug for treatment of
geographic atrophy that is currently under evaluation for safety and efficacy by
the U.S. FDA
    ** In a combined analysis of GATHER1 and GATHER2 clinical trials patients
treated with ACP experienced a 56% reduction - ISEE
    ** Adds the two trials independently showed a 44% and 59% reduction,
respectively, in the rate of vision loss
    ** Geographic atrophy is an age-related disorder which leads to visual
function loss
    ** Co gained ~28% last year

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))